CO5251405A1 - 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il- 4-o-tolil-piridin-3-il)-isobutiramida - Google Patents

2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il- 4-o-tolil-piridin-3-il)-isobutiramida

Info

Publication number
CO5251405A1
CO5251405A1 CO00090625A CO00090625A CO5251405A1 CO 5251405 A1 CO5251405 A1 CO 5251405A1 CO 00090625 A CO00090625 A CO 00090625A CO 00090625 A CO00090625 A CO 00090625A CO 5251405 A1 CO5251405 A1 CO 5251405A1
Authority
CO
Colombia
Prior art keywords
compound
formula
isobutiramida
tolil
trifluorometil
Prior art date
Application number
CO00090625A
Other languages
English (en)
Inventor
Theresa Maria Ballard
Guy Andrew Higgins
Torsten Hoffmann
Sonia Maria Poli
Andrew Sleight
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO5251405A1 publication Critical patent/CO5251405A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

El compuesto de la fórmula<EMI FILE="00090625_1" ID="1" IMF=JPEG >IUn procedimiento para la preparación del compuesto de fórmula I como se ha definido en la reivindicación 1, cuyo procedimiento comprende hacer reaccionar un compuesto de la fórmula <EMI FILE="00090625_2" ID="2" IMF=JPEG >con un compuesto de la fórmula<EMI FILE="00090625_3" ID="3" IMF=JPEG >para formar un compuesto de la fórmula<EMI FILE="00090625_4" ID="4" IMF=JPEG >y,si se desea, convertir el compuesto obtenido en una sal de adición de ácido farmacèuticamente aceptable.
CO00090625A 1999-11-29 2000-11-27 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il- 4-o-tolil-piridin-3-il)-isobutiramida CO5251405A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99123685 1999-11-29

Publications (1)

Publication Number Publication Date
CO5251405A1 true CO5251405A1 (es) 2003-02-28

Family

ID=8239481

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00090625A CO5251405A1 (es) 1999-11-29 2000-11-27 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il- 4-o-tolil-piridin-3-il)-isobutiramida

Country Status (50)

Country Link
EP (1) EP1103545B1 (es)
JP (1) JP3480835B2 (es)
KR (1) KR100390117B1 (es)
CN (1) CN1152016C (es)
AR (1) AR033659A1 (es)
AT (1) ATE253561T1 (es)
AU (1) AU775292B2 (es)
BG (1) BG64622B1 (es)
BR (1) BRPI0005616B8 (es)
CA (1) CA2326529C (es)
CO (1) CO5251405A1 (es)
CZ (1) CZ299286B6 (es)
DE (2) DE60006340T2 (es)
DK (1) DK1103545T3 (es)
DO (1) DOP2000000106A (es)
EA (1) EA004404B1 (es)
ES (2) ES2208205T3 (es)
FR (1) FR2801590A1 (es)
GB (1) GB2356863A (es)
GC (1) GC0000151A (es)
GE (1) GEP20022763B (es)
GT (1) GT200000197A (es)
HK (1) HK1036759A1 (es)
HR (1) HRP20000809A2 (es)
HU (1) HU224703B1 (es)
ID (1) ID28483A (es)
IL (1) IL139868A (es)
IS (1) IS2212B (es)
IT (1) IT1320120B1 (es)
JO (1) JO2298B1 (es)
MA (1) MA26754A1 (es)
MX (1) MXPA00011672A (es)
MY (1) MY127426A (es)
NO (1) NO317264B1 (es)
NZ (1) NZ508386A (es)
OA (1) OA11513A (es)
PA (1) PA8507201A1 (es)
PE (1) PE20010901A1 (es)
PL (1) PL195957B1 (es)
PT (1) PT1103545E (es)
SG (1) SG97171A1 (es)
SI (1) SI1103545T1 (es)
SK (1) SK285373B6 (es)
SV (1) SV2002000227A (es)
TN (1) TNSN00226A1 (es)
TR (1) TR200302077T4 (es)
UA (1) UA70326C2 (es)
UY (1) UY26458A1 (es)
YU (1) YU73400A (es)
ZA (1) ZA200006964B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000050398A2 (en) * 1999-02-24 2000-08-31 F. Hoffmann-La Roche Ag Phenyl- and pyridinyl derivatives as neurokinin 1 antagonists
EP1035115B1 (en) * 1999-02-24 2004-09-29 F. Hoffmann-La Roche Ag 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
WO2002006236A1 (en) * 2000-07-14 2002-01-24 F. Hoffmann-La Roche Ag N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
KR20040077910A (ko) * 2002-01-31 2004-09-07 에프. 호프만-라 로슈 아게 프리프로타키키닌 유전자의 유전자 다형성
JP4490421B2 (ja) 2003-07-03 2010-06-23 エフ．ホフマン−ラ ロシュ アーゲー 統合失調症を処置するデュアルｎｋ１／ｎｋ３アンタゴニスト
TWI280239B (en) 2003-07-15 2007-05-01 Hoffmann La Roche Process for preparation of pyridine derivatives
JP4580426B2 (ja) 2004-07-06 2010-11-10 エフ．ホフマン−ラ ロシュ アーゲー Ｎｋ−１受容体拮抗薬の合成において中間体として使用されるカルボキサミド誘導体の製造方法
EP1855655A2 (en) 2005-02-25 2007-11-21 F. Hoffmann-Roche AG Tablets with improved drug substance dispersibility
RU2404969C2 (ru) * 2005-03-23 2010-11-27 Ф. Хоффманн-Ля Рош Аг Метаболиты антагонистов nk-1 против рвоты
CN101267808A (zh) * 2005-09-23 2008-09-17 弗·哈夫曼-拉罗切有限公司 新型制剂
WO2008090114A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
US8426450B1 (en) * 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
MY183637A (en) 2013-03-15 2021-03-04 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
EP3067349B1 (en) 2013-11-08 2018-02-28 Kissei Pharmaceutical Co., Ltd. Carboxymethyl piperidine derivative
PT3102208T (pt) 2014-02-07 2021-04-05 Global Blood Therapeutics Inc Polimorfos cristalinos da base livre de 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)piridin-3 il)metoxi)benzaldeído
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
KR101948238B1 (ko) 2016-08-19 2019-02-14 (주)케어젠 미녹시딜과 펩타이드의 결합체

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT533280E (pt) * 1991-09-20 2001-01-31 Glaxo Group Ltd Novas utilizacoes medicas para antagonistas de taquiquinina
IL106142A (en) * 1992-06-29 1997-03-18 Merck & Co Inc Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them
IL111960A (en) * 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
EP1462450B1 (en) * 1993-12-29 2007-06-13 MERCK SHARP &amp; DOHME LTD. Substituted morpholine derivatives and their use as therapeutic agents
TW385308B (en) * 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
ATE242243T1 (de) * 1995-03-24 2003-06-15 Takeda Chemical Industries Ltd Zyklische verbindungen, ihre herstellung und ihre verwendung als tachykininrezeptorantagonisten
US5972938A (en) * 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
EP1035115B1 (en) * 1999-02-24 2004-09-29 F. Hoffmann-La Roche Ag 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
WO2002006236A1 (en) * 2000-07-14 2002-01-24 F. Hoffmann-La Roche Ag N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives

Also Published As

Publication number Publication date
SI1103545T1 (en) 2004-02-29
SV2002000227A (es) 2002-02-05
GT200000197A (es) 2002-05-22
BG104992A (en) 2001-11-30
AR033659A1 (es) 2004-01-07
ITMI20002575A1 (it) 2002-05-29
BG64622B1 (bg) 2005-09-30
NZ508386A (en) 2003-02-28
NO20006012D0 (no) 2000-11-28
IL139868A (en) 2009-09-01
ZA200006964B (en) 2001-06-05
DE10058310A1 (de) 2001-05-31
MA26754A1 (fr) 2004-12-20
OA11513A (fr) 2004-02-03
KR100390117B1 (ko) 2003-07-04
AU775292B2 (en) 2004-07-29
CN1297888A (zh) 2001-06-06
HU224703B1 (en) 2006-01-30
CA2326529C (en) 2009-12-22
HUP0004725A2 (hu) 2002-04-29
NO20006012L (no) 2001-05-30
AU7178700A (en) 2001-05-31
MY127426A (en) 2006-11-30
JO2298B1 (en) 2005-09-12
EP1103545B1 (en) 2003-11-05
CN1152016C (zh) 2004-06-02
HRP20000809A2 (en) 2001-12-31
BRPI0005616B1 (pt) 2017-12-12
NO317264B1 (no) 2004-09-27
JP2001151754A (ja) 2001-06-05
KR20010051983A (ko) 2001-06-25
ES2208205T3 (es) 2004-06-16
ID28483A (id) 2001-05-31
IT1320120B1 (it) 2003-11-18
DE60006340D1 (de) 2003-12-11
PE20010901A1 (es) 2001-09-20
FR2801590A1 (fr) 2001-06-01
SG97171A1 (en) 2003-07-18
YU73400A (sh) 2003-02-28
GEP20022763B (en) 2002-08-26
PA8507201A1 (es) 2002-02-21
SK17932000A3 (sk) 2001-11-06
EP1103545A1 (en) 2001-05-30
BR0005616A (pt) 2001-07-17
DK1103545T3 (da) 2004-03-15
DOP2000000106A (es) 2002-07-30
JP3480835B2 (ja) 2003-12-22
SK285373B6 (sk) 2006-12-07
MXPA00011672A (es) 2002-08-20
GB2356863A (en) 2001-06-06
PL344147A1 (en) 2001-06-04
CA2326529A1 (en) 2001-05-29
DE60006340T2 (de) 2004-09-09
GC0000151A (en) 2005-06-29
CZ299286B6 (cs) 2008-06-04
EA200001114A2 (ru) 2001-08-27
HU0004725D0 (es) 2001-02-28
UA70326C2 (en) 2004-10-15
HK1036759A1 (en) 2002-01-18
IS2212B (is) 2007-02-15
IS5725A (is) 2001-05-29
BRPI0005616B8 (pt) 2021-07-06
CZ20004399A3 (cs) 2001-07-11
EA200001114A3 (ru) 2001-12-24
PT1103545E (pt) 2004-03-31
GB0028566D0 (en) 2001-01-10
ES2171134A1 (es) 2002-08-16
TNSN00226A1 (fr) 2002-05-30
ATE253561T1 (de) 2003-11-15
TR200302077T4 (tr) 2004-01-21
IL139868A0 (en) 2002-02-10
PL195957B1 (pl) 2007-11-30
EA004404B1 (ru) 2004-04-29
UY26458A1 (es) 2001-05-31

Similar Documents

Publication Publication Date Title
CO5251405A1 (es) 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il- 4-o-tolil-piridin-3-il)-isobutiramida
CO5280060A1 (es) Aminoacidos biciclicos como agentes farmaceuticos
CO5271657A1 (es) Derivados de azaindol
CO5460265A1 (es) Compuestos quimicos
CO5251404A1 (es) Compuestos antibioticos de azalida
AR050709A1 (es) Metodo para preparar irbesartan e intermediarios del mismo
CO5271736A1 (es) Forma triturada
EA199800563A1 (ru) Антагонисты гормона, высвобождающего гонадотропин
CO5160253A1 (es) Complejo de 1,4-benzodiazepinas sustituidas y sulfobutileter -7-ciclodextrina o 2-hidroxipropil-b-ciclodextrina .
EA200101194A1 (ru) Производные 4,5,6,7-тетрагидроиндазола в качестве противоопухолевых средств
CO5200785A1 (es) Uso terapeutico de quinazolina
PE20021059A1 (es) Compuestos de triazol utiles en el tramiento de enfermedades asociadas con la actividad no deseada de citoquinas
CO5271666A1 (es) Derivados de pirimidina
BR0109048A (pt) Processo para a sìntese de citalopram
CO5180605A1 (es) Compuestos de indol
BR0115121A (pt) Compostos n-((1,2,4)triazoloazinil)tiofenossulfonamida como herbicidas
CO5090837A1 (es) Derivados de 1,3,4-oxadiazolona
CO5160260A1 (es) Secretagogos de la hormona del crecimiento derivados de imi- dazol 1,4- substituido
CO5200762A1 (es) Preparacion de piperidin-4-onas sustituidas
AU2003267551A1 (en) Thieno-pyrrole compounds as antagonists of gonadotropin releasing hormone
CO5190690A1 (es) Compuestos quimicos sustituidos, como inhibidores de cinasa deshidrogenasa de pi ruvato
GB0011071D0 (en) Organic compounds
CO5271723A1 (es) Forma triturada
CO5090902A1 (es) Pirroles sustituidos
CO5270005A1 (es) Un nuevo proceso de prepracion de derivados del 2-amino indano

Legal Events

Date Code Title Description
FG Application granted